18-Feb-2026
TipRanks (Wed, 18-Feb 8:10 AM ET)
Notable healthcare headlines for the week: AstraZeneca, CVS Health, and Moderna in focus
Seeking Alpha News (Sun, 15-Feb 9:05 AM ET)
Baxter's Q4 Results Highlight Shift to Innovation and International Growth Amid Ongoing Challenges
Market Chameleon (Thu, 12-Feb 2:32 AM ET)
Baxter Reports Fourth-Quarter 2025 Results
Business Wire (Thu, 12-Feb 7:15 AM ET)
Globe Newswire (Thu, 5-Feb 10:50 AM ET)
Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors
Business Wire (Wed, 21-Jan 5:00 PM ET)
Business Wire (Tue, 13-Jan 9:00 AM ET)
Business Wire (Thu, 8-Jan 9:00 AM ET)
Baxter to Present at J.P. Morgan 2026 Healthcare Conference
Business Wire (Tue, 6-Jan 5:14 PM ET)
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.
Baxter International trades on the NYSE stock market under the symbol BAX.
As of February 18, 2026, BAX stock price climbed to $21.87 with 13,129,665 million shares trading.
BAX has a beta of 1.14, meaning it tends to be more sensitive to market movements. BAX has a correlation of 0.15 to the broad based SPY ETF.
BAX has a market cap of $11.25 billion. This is considered a Large Cap stock.
Last quarter Baxter International reported $3 billion in Revenue and $.44 earnings per share. This beat revenue expectation by $163 million and missed earnings estimates by -$.09.
In the last 3 years, BAX traded as high as $50.21 and as low as $17.40.
The top ETF exchange traded funds that BAX belongs to (by Net Assets): VTI, VOO, VB, RSP, VBR.
BAX has underperformed the market in the last year with a return of -28.2%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in BAX shares. However, BAX has outperformed the market in the last 3 month and 2 week periods, returning +20.6% and +4.0%, while SPY returned +4.3% and 0.0%, respectively. This indicates BAX has been having a stronger performance recently.
BAX support price is $20.22 and resistance is $21.27 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BAX shares will trade within this expected range on the day.